Nasus Pharma announced its intranasal epinephrine powder formulation NS002 achieved significantly faster delivery to therapeutic threshold compared to EpiPen in a Phase 2 clinical study of 50 healthy adults.
- NS002 reached critical 100 pg/mL threshold in 1.69 minutes versus 3.42 minutes for EpiPen
- At 5 minutes, 88.4% of NS002 subjects reached therapeutic threshold compared to 64.6% with EpiPen
- Drug demonstrated favorable safety profile with no serious adverse events reported
- Nasus plans to initiate pivotal clinical study in fourth quarter of 2026
To view the source of this information, click
To contact the reporter on this story:
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.